SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody

Contact us
ProSci
Product Code: PSI-9185
Product Group: Primary Antibodies
Supplier: ProSci
CodeSizePrice
PSI-9185-0.02mg0.02mg£150.00
Quantity:
PSI-9185-0.1mg0.1mg£449.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
blue ice or RT
Storage:
SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Images

1 / 2
<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) NSP14 in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) NSP14 antibody (9185, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 NSP14 protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.
2 / 2
<strong>Figure 2 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody, 9185. A direct ELISA was performed using immunogen peptide (9185P) as coating antigen and the anti-SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.
❮❯

<strong>Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) NSP14 in COVID-19 Patient Lung</strong><br> Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) NSP14 antibody (9185, 0.5 μg/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 NSP14 protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.
<strong>Figure 2 ELISA Validation </strong><br> Antibodies: SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody, 9185. A direct ELISA was performed using immunogen peptide (9185P) as coating antigen and the anti-SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000ng/mL.

Documents

Further Information

Additional Names:
Proofreading exoribonuclease, Guanine-N7 methyltransferase, Non-structural protein 14, NSP14.
Application Note:
IHC: 0.5 μg/mL .

Antibody validated: Immunohistochemistry in human samples. SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody can detect 2 ng of free peptide at 1 μg/mL in ELISA. All other applications and species not yet tested
Background:
Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019?20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP14 (ExoN) is an enzyme possessing two different activities: an exoribonuclease activity acting on both ssRNA and dsRNA in a 3' to 5' direction and a N7-guanine methyltransferase activity (3,4,5). It acts as a proofreading exoribonuclease for RNA replication, thereby lowering The sensitivity of the virus to RNA mutagens(6,7,8).
Background References:
  • Gorbalenya. bioRxiv: 2020.
  • Hui et al. Int J Infect Dis. 2020;91:264-266.
  • Minskaia et. al. Proc. Natl. Acad. Sci. U.S.A 2006; 103:5108-5113
  • Bouvet et. al. PLoS Pathog. 2010; 6:E1000863-E1000863
  • Bouvet et. al. Proc. Natl. Acad. Sci. U.S.A. 2012;109:9372-9377
  • Denison et. al. RNA Biol. 2011;8:270-279
  • Smith et. al. PLoS Pathog. 2013;9:e1003565-e1003565
  • Agostini et. al. MBio 2018; 9:0-0
Buffer:
SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted reactivity based on immunogen sequence: SARS-CoV NSP14 (ExoN) protein: (79%).
Immunogen:
Anti-SARS-CoV-2 (COVID-19) NSP14 (ExoN) antibody (9185) was raised against a peptide corresponding to 14 amino acids near the center of SARS-CoV-2 (COVID-19) NSP14 (ExoN) protein.

The immunogen is located between 120-170 amino acids of SARS-CoV-2 (COVID-19) NSP14 (ExoN).
NCBI Gene ID #:
43740578
NCBI Official Name:
ORF1a polyprotein;ORF1ab polyprotein
NCBI Official Symbol:
ORF1ab
NCBI Organism:
Severe acute respiratory syndrome coronavirus 2
Physical State:
Liquid
Protein Accession #:
YP_009725309.1
Protein GI Number:
1802476817
Purification:
SARS-CoV-2 (COVID-19) NSP14 (ExoN) Antibody is affinity chromatography purified via peptide column.
Research Area:
Infectious Disease,COVID-19
Swissprot #:
P0DTC1
User NOte:
Optimal dilutions for each application to be determined by the researcher.